Novo Nordisk A/S – Share repurchase programme
02 November 2021 - 9:02PM
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 2 November
2021 – On 4 August 2021, Novo Nordisk initiated a
share repurchase programme in accordance with Article 5 of
Regulation No 596/2014 of the European Parliament and Council of 16
April 2014 (MAR) and the Commission Delegated Regulation (EU)
2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This
programme is part of the overall share repurchase programme of up
to DKK 18 billion to be executed during a 12-month period beginning
3 February 2021.
Under the programme initiated 4 August 2021, Novo Nordisk has
repurchased B shares for an amount up to DKK 3.3 billion in the
period from 5 August 2021 to 1 November 2021. The programme is now
concluded.
Since the announcement 25 October 2021, the following
transactions have been made:
|
|
Number ofB shares |
Averagepurchase price |
Transactionvalue, DKK |
|
Accumulated, last announcement |
4,664,367 |
|
2,992,853,553 |
| 25 October
2021 |
75,000 |
680.60 |
51,044,797 |
| 26 October
2021 |
75,000 |
677.59 |
50,819,295 |
| 27 October
2021 |
75,000 |
682.15 |
51,161,384 |
| 28 October
2021 |
75,000 |
682.45 |
51,184,007 |
| 29 October
2021 |
74,000 |
692.58 |
51,250,970 |
| 1 November
2021 |
73,400 |
703.55 |
51,640,661 |
|
Accumulated under the programme |
5,111,767 |
|
3,299,954,667 |
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of
22,633,347 B shares of DKK 0.20 as treasury shares, corresponding
to 1.0% of the share capital. The total amount of A and B shares in
the company is 2,310,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to
DKK 18 billion during a 12-month period beginning 3 February 2021.
As of 1 November 2021, Novo Nordisk has since 3 February 2021
repurchased a total of 23,826,181 B shares at an average share
price of DKK 511.47 per B share equal to a transaction value of DKK
12,186,313,644.
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change
to defeat diabetes and other serious chronic diseases such as
obesity and rare blood and endocrine disorders. We do so by
pioneering scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 45,800 people in 80 countries and markets its
products in around 170 countries. Novo Nordisk's B shares are
listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the
New York Stock Exchange (NVO). For more information, visit
novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
| Media: |
|
|
| Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
| Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
| |
|
|
| Investors: |
|
|
| Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
| Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
| David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
| Mark Joseph Root
(US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
Company announcement No 65 /2021
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jan 2025 to Feb 2025
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Feb 2024 to Feb 2025
